Streetbeat News

Stock Prices

IVVD

Invivyd has announced promising 180-day exploratory clinical efficacy data from its CANOPY Phase 3 trial of Pemivibart, showing an 84% relative risk reduction in symptomatic COVID-19 compared to a placebo.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:02 am

AUTL

Autolus Therapeutics (NASDAQ:AUTL) will present data on tumor burden-guided dosing at the SOHO 2024 Annual Meeting. The data focuses on the impact of bone marrow blast percentage in patients with relapsed/refractory B-Cell Acute Lymphoblastic Leukemia treated with obe-cel.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:02 am

CAVA

NVDA

PARA

U.S. stocks are experiencing a mixed start as traders await Nvidia's earnings and inflation data. Analysts suggest a shift from volatile tech stocks to dividend-paying stocks. Paramount Global and CAVA Group saw significant premarket declines due to strategic changes and insider sales, respectively.

Portfolio Pulse from Shanthi Rexaline

August 27, 2024 | 10:59 am

CTRN

Citi Trends anticipates a mid-single digit decline in sales for 2024, attributed to the absence of a 53rd week and store closures.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:53 am

CTRN

Citi Trends projects flat to low-single digit growth in comparable store sales for the second half of 2024 compared to 2023. Total sales are expected to decline due to a 53rd week in the previous year and store closures. The company plans to close 10-15 underperforming stores and expects a year-end cash balance of $60-70 million.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:53 am

SMFL

Smart for Life shares are experiencing an uptick following the company's announcement of negotiations for four Health & Wellness acquisitions.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:51 am

LLY

Eli Lilly has announced that Zepbound (Tirzepatide) 2.5 mg and 5 mg single-dose vials are now available for self-pay patients with an on-label prescription. The pricing is competitive, being less than half the list price of other incretin medicines for obesity.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:48 am

CTRN

Citi Trends reported a Q2 2024 GAAP EPS of $(2.21), which may not be comparable to the estimated $(0.60). The company's sales were $176.552 million, missing the $179.125 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:47 am

AXP

CAT

NVDA

U.S. markets closed mixed with the S&P 500 and Nasdaq declining, while the Dow rose. Nvidia's stock fell ahead of its earnings report. Durable goods orders in the U.S. increased by 9.9% in July. Asian markets showed mixed results, and European markets edged up. Commodities like crude oil and gold retreated.

Portfolio Pulse from Akanksha Bakshi

August 27, 2024 | 10:46 am

GOTU

Gaotu Techedu's shares are declining after the company reported a Q2 earnings miss.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:46 am